
Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks. Maintaining glycemic control over time is a significant challenge because of the progressive nature of diabetes as a result of declining β-cell function. This article identifies complications of non-insulin treatments for diabetes. The major classes of medications are reviewed with special focus on target population, mechanism of action, effect on weight, cardiovascular outcomes and additional class-specific side effects including effects on bone. Effects on β-cell function are also highlighted.
Biguanides, Islet Amyloid Polypeptide, Sulfonylurea Compounds, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Insulin-Secreting Cells, Humans, Hypoglycemic Agents, Glycoside Hydrolase Inhibitors, Thiazolidinediones, Insulin Resistance
Biguanides, Islet Amyloid Polypeptide, Sulfonylurea Compounds, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Insulin-Secreting Cells, Humans, Hypoglycemic Agents, Glycoside Hydrolase Inhibitors, Thiazolidinediones, Insulin Resistance
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 34 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
